Evidence map›Paper›PMID 39466390›Full record

ArticlePediatric nephrology (Berlin, Germany)2025

Real-world evidence of lisinopril in pediatric hypertension and nephroprotective management: a 10-year cohort study.

Eva Degraeuwe, Elke Gasthuys, Evelien Snauwaert, Lien Dossche, Agnieszka Prytula, Joke Dehoorne, An Vermeulen, Johan Vande Walle, Ann Raes

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Eva DegraeuweDepartment of Internal Diseases and Pediatrics, Faculty of Health and Medical Sciences, Ghent University, Ghent, Belgium. eva.degraeuwe@ugent.be.ORCID http://orcid.org/0000-0003-2523-3022
Elke GasthuysLaboratory of Medical Biochemistry and Clinical Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Evelien SnauwaertDepartment of Internal Diseases and Pediatrics, Faculty of Health and Medical Sciences, Ghent University, Ghent, Belgium.
Lien DosscheDepartment of Internal Diseases and Pediatrics, Faculty of Health and Medical Sciences, Ghent University, Ghent, Belgium.
Agnieszka PrytulaDepartment of Internal Diseases and Pediatrics, Faculty of Health and Medical Sciences, Ghent University, Ghent, Belgium.
Joke DehoorneDepartment of Internal Diseases and Pediatrics, Faculty of Health and Medical Sciences, Ghent University, Ghent, Belgium.
An VermeulenLaboratory of Medical Biochemistry and Clinical Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Johan Vande WalleDepartment of Internal Diseases and Pediatrics, Faculty of Health and Medical Sciences, Ghent University, Ghent, Belgium.
Ann RaesDepartment of Internal Diseases and Pediatrics, Faculty of Health and Medical Sciences, Ghent University, Ghent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOver the last 20 years, pediatric hypertension (pHTN) prevalence in Western society has risen from 3.5 to 9% due to childhood overweight, obesity, and secondary kidney and cardiological conditions. Few studies have assessed commonly used antihypertensive medication lisinopril's (ACE-inhibitor) long-term efficacy and the long-term value of renin-angiotensin-aldosterone system (RAAS) biomarkers.

methodsThis is a retrospective cohort study at Ghent University Hospital, Belgium, with 106 young patients (1-18 years) treated with lisinopril due to hypertension (HTN) and chronic kidney disease (CKD) assessed for treatment outcomes against clinical benchmarks over 10 years.

resultsLisinopril was mainly initiated for secondary hypertension or nephroprotection (89%) due to kidney causes. A starting dose across groups was lower than 0.07 mg/kg for 48% (n = 50). HTN patients without CKD achieved systolic blood pressure below the 95th percentile within 2 years, but efficacy declined after 2.5 years. CKD patients maintained a steady response, reaching systolic targets by 40 months and showing improved diastolic control over 70 months. Proteinuria reduction had a median urine protein creatinine ratio (UPCR) to 0.57 g/g at 6 months, with a reappearance of UPCR 2 g/g creatinine after 40 months. Aldosterone breakthrough occurred from 6 months onward in all groups. Over 70 months, aldosterone and aldosterone-renin-ratio (ARR) progression significantly differ between children with and without normal kidney function.

conclusionsTreatment efficacy for systolic blood pressure in hypertensive patients with abnormal kidney function diminishes after 2.5 years and for proteinuria in children after 3 years, highlighting the need for dosage recalibration according to guidelines and/or the need for alternative treatments.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsHypertensionLisinoprilRenal Insufficiency, ChronicAdolescentBelgiumBlood PressureChildChild, PreschoolFemaleHumansInfantMaleProteinuriaRenin-Angiotensin SystemAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsLisinoprilACE-inhibitorHypertensionLisinoprilPediatrics

Identifiers

PMID39466390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.